医学
胸腺瘤
彭布罗利珠单抗
胸腺癌
内科学
胃肠病学
重症肌无力
化疗
外科
不利影响
癌症
免疫疗法
作者
Jinhyun Cho,Hae Su Kim,Bo Mi Ku,Yoon‐La Choi,Răzvan Cristescu,Joungho Han,Jong‐Mu Sun,Se‐Hoon Lee,Jin Seok Ahn,Keunchil Park,Myung‐Ju Ahn
标识
DOI:10.1200/jco.2017.77.3184
摘要
Pembrolizumab showed encouraging antitumor activity in patients with advanced TET. Given the high incidence of autoimmunity, additional studies are needed to identify those who can benefit from pembrolizumab without immune-related adverse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI